ViewPoints Article: 5 Technologies That Redefines Human Medicine and Therapeutics
Ironwood Terminated Rights of Zurampic lesinurad and Duzallo lesinurad/allopurinol Deal with AZ
Ironwood Terminated Rights of Zurampic lesinurad and Duzallo lesinurad/allopurinol Deal with AZ
Shots:
- As per Ironwood Zurampic generated $1.1Mn in 2Q18 and $3.1 Mn in 2017, company to reduce 125 field sales employees
- This termination agreement is expected to save $75-$100Mn in FY19 expenses
- This deal was executed in 2016 with Ironwood paying $100Mn upfront followed by $15Mn milestone payment post approval in US along with single-digit royalties
